ScreenerHero
RXBioSyent Inc.
TSXV · CA · Healthcare · Drug Manufacturers - Specialty & Generic · biosyent.com
15.63CAD+2.49%Mkt Cap: 120.49M $P/E: 18.72

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.19BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$15.34BUSDP/E 117.3
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
SFZN
Siegfried Holding AG
$4.01BUSDP/E 20.9
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
HIK
Hikma Pharmaceuticals PLC
$3.69BUSDP/E 12.7
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap120.49M $
Enterprise Value118.75M $
Revenue (TTM)33.49M $
Gross Profit24.01M $
Net Income (TTM)6.56M $
Revenue/Share2.969 USD
Last Price15.63 CAD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees—
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)18.72
P/E (Forward)26.34
PEG—
EV/EBITDA13.00
EV/Revenue3.55
P/S3.64
P/B3.75
EPS (TTM)0.78
EPS (Forward)0.56
52W Range
10.6597% of range15.80
52W High15.80 CAD
52W Low10.65 CAD
Profitability
Gross Margin76.57%
Oper. Margin24.61%
EBITDA Margin27.29%
Profit Margin20.93%
ROE21.73%
ROA18.23%
Growth
Revenue Growth26.70%
Earnings Growth0.50%
Cash Flow & Leverage
Operating CF6.56M $
CapEx (TTM)283.88K $
FCF Margin13.16%
FCF Yield3.66%
Net Debt-4.12M $
Net Debt/EBITDA-0.45
Balance Sheet
Debt/Equity0.02
Current Ratio1.89
Quick Ratio1.11
Book Value/Sh3.935 CAD
Cash/Share0.9530 CAD
Dividends
Fwd Div Rate0.2200 CAD
Trail. Div Rate0.2050 CAD
Div. Yield1.49%
5Y Avg Yield—
Payout Ratio26.15%
Ex-Div DateMay 29, 2026
Pay DateJun 15, 2026
Analyst Consensus
Rating—
Target (Mean)18.00 CAD
Upside (mean)+15.2%
Target Range18.00 CAD – 18.00 CAD
# Analysts1
Ownership
Shares Out.11.33M
Float9.25M
Insiders34.86%
Institutions3.99%
Short Interest
Short Ratio0.1d
Short % Out.0.00%
Shares Short1.38K
Short (prev mo.)2.57K
Technical
SMA 5014.53 (+7.6%)
SMA 20013.84 (+12.9%)
Beta0.63
S&P 52W Chg18.16%
Avg Vol (30d)12.53K
Avg Vol (10d)9.60K
Technical Indicators
RSI (14)61.4
MACD0.1743
MACD Signal0.1690
MACD Hist.+0.0053
BB Upper15.44 CAD
BB Middle14.84 CAD
BB Lower14.24 CAD
BB Width8.10%
ATR (14)0.2712 CAD
Vol Ratio (20d)0.02x